Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service

Therapeutic Drug Monitoring

Volumn 16, Issue 4, 1994, Pages 368-374

  Jerling, Markus ^a   Lindstrm, Leif ^b   Bondesson, Ulf ^b   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Caffeine; Carbamazepine; Clozapine; CYP1A2; CYP2D6; CYP3A4; Drug interactions; Fluvoxamine

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; DIAZEPAM; FLUNITRAZEPAM; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; NITRAZEPAM; PERPHENAZINE; REMOXIPRIDE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADULT; AGED; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES;

EID: 0028318482     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/00007691-199408000-00006     Document Type: Article

References (37)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double blind comparison versus chlorpromazine. Arch Gen Psychiatry1988;45: 789-796.
2. Lieberman JA, Alvir JM. A report of clozapine-induced agranulocytosis in the United States. Drug Safety1992;7 (suppl 1): 1-2.
3. Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Safety1992;7(suppl 1): 17-25.
4. Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit1994;16:1-12.
5. Br0sen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol1993;45:1211-1214.
6. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics1993;3:61-70.
7. Br0sen K, Gram LF. Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol1989;36:537-547.
8. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos1985;13:443-448.
9. Syvalahti EK, Lindberg R, Kallio J, De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol1986;22:89-92.
10. Spina E, Martines C, Caputi AP, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol1991;41:467-470.
11. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther1991; 49:234-240.
12. Dahl ML, Ekqvist B, Wid6n J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand1991;84:99-102.
13. Llerena A, Aim C, Dahl ML, Ekqvist B, Bertilsson L. Halo-peridol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit1992;14:92-97.
14. Dahl-Puustinen ML, Liddn A, Aim C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther1989;46:78-81.
15. Steiner E, Movin G, Lindeberg A, Nilsson L, Wahldn A. The elimination of remoxipride—a new dopamine 02-receptor antagonist—covaries with the ability to hydroxyl-ate debrisoquine. Presented at the Twenty-fourth Nordic Meeting of Pharmacology, Toxicology and Clinical Pharmacology, Reykjavik, Iceland, 1989.
16. Bondesson U, Lindstrom LH. Determination of clozapine and its /V-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology1988;95:472-475.
17. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokin Biop harm1981;9:503-512.
18. Haring C, Meise U, Humpel C, et al. Dose-related plasmaconcentrations of clozapine: influence of smoking behaviour, sex, and age. Psychopharmacology1989;99:38-40.
19. Ackenheil M. Clozapine: pharmacokinetic investigations and biochemical effects. Psychopharmacology1989;99: 32-37.
20. Rosenthaler J, Nimmerfall F, Sigrist R, Munzer H. Nonequilibrium method for the radioimmunoassay of clozapine in the presence of metabolites. Eur J Biochem1977;80: 603-609.
21. Fischer B, Vogels G, Maurer G, Tynes RE. The antipsychotic clozapine is metabolized by the polymorphic human microsomal recombinant cytochrome P4502D6. J Pharmacol Exp Ther1992;260:1355-1360.
22. Dahl ML, Llerena A, Bondesson U, Lindstrom L, Bertils-son L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol1994;37:71-74.
23. Szymanski S, Lieberman JL, Picou D, Masiar S, Cooper T. A case report of cimetidine induced clozapine toxicity. J Clin Psychiatry1991;52:21-22.
24. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry1991;52:23-25.
25. Raitasuo V, Lehtovaara R, Nuttunen MO. Carbamazepine and plasma levels of clozapine [Letter]. Am J Psychiatry1993;150:169.
26. Moreland TA, Park BK, Rylance GW. Microsomal enzyme induction in children: The influence of carbamazepine treatment on antipyrine kinetics, 6 3-hydroxycortisol excretion and plasma 7-glutamyltranspeptidase activity.Br J Clin Pharmacol1982;14:861-865.
27. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6 3-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.Br J Clin Pharmacol1989;28:373-387.
28. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipra-mine in four patients. Ther Drug Monit1992;14:194-196.
29. Skjelbo E, Br0sen K. Inhibitors of imipramine metabolism by human liver microsomes.Br J Clin Pharmacol1992;34: 256-261.
30. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand1991;84: 583-584.
31. Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine [Letter]. Br J Clin Pharmacol1993;36:615.
32. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Flu-voxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol1991;40:119-120.
33. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol1988;26:363-372.
34. Okey AB. Enzyme induction in the cytochrome P-450 system. In: Kalow W, ed. Pharmacogenetics of drug metabolism.New York: Pergamon Press, 1992: 549-608.
35. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther1987;42:157-165.
36. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika1986;73:645-656.
37. Sheiner LB, Beal S, Rosenberg B, Marathe V. Forecasting individual pharmacokinetics. Clin Pharmacol Ther1979;31: 294-305.